Systemic treatment-induced gastrointestinal toxicity: Incidence, clinical presentation and management
Date
2012Source
Annals of GastroenterologyVolume
25Issue
2Pages
106-118Google Scholar check
Keyword(s):
Metadata
Show full item recordAbstract
The toxicity of cancer chemotherapy is among the most important factors limiting its use. Clear delineation and communication of benefits and risks is an essential component of treatment decisions. Gastrointestinal toxicity during chemotherapy is frequent and contributes to dose reductions, delays and cessation of cancer treatment. The development of intervention strategies that could eliminate an expected side effect of chemotherapy is vital. Physiologic changes that can increase the toxicity of chemotherapy are decreased stem cell reserves, decreased ability to repair cell damage, progressive loss of body protein, and accumulation of body fat. Symptoms only arise when physiological functions are altered. The gastrointestinal symptoms arising during cancer chemotherapy can often be cured if newly acquired, and if gastrointestinal physiological deficits are identified. Developing new chemotherapy regimens with similar efficacy but less toxicity should be a priority for future research. © 2012 Hellenic Society of Gastroenterology.
Collections
Cite as
Related items
Showing items related by title, author, creator and subject.
-
Article
Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study
Pappas, P.; Karavasilis, V.; Briassoulis, E. Ch; Pavlidis, Nicholas; Marselos, M. (2005)Aim: To evaluate the pharmacokinetics of imatinib mesylate (Glivec) and its main metabolite (CGP74588) in a patient with end stage renal disease on hemodialysis and compare it with published data from subjects with normal ...
-
Article
Feasibility study and pharmacokinetics of low-dose paclitaxel in cancer patients with severe hepatic dysfunction
Briassoulis, E. Ch; Karavasilis, V.; Tzamakou, E.; Piperidou, C.; Soulti, K.; Pavlidis, Nicholas (2006)The aim of this study is to investigate the feasibility and determine the pharmacokinetics of low-dose paclitaxel in cancer patients with severe hepatic dysfunction. This was a prospective study. Patients with liver ...
-
Article
Liver metastases from cancer of unknown primary (CUPL): A retrospective analysis of presentation, management and prognosis in 49 patients and systematic review of the literature
Lazaridis, G.; Pentheroudakis, George; Fountzilas, George; Pavlidis, Nicholas (2008)Aim: Patients with liver metastases from cancer of unknown primary (CUPL) have a dismal prognosis. We retrospectively analysed their management and outcome and performed a systematic review of CUPL series published in the ...